A method of evaluating pancreatic cancer includes (I) an obtaining step of obtaining amino acid concentration data on a concentration value of an amino acid in blood collected from a subject to be evaluated, and (II) an evaluating step of evaluating a state of pancreatic cancer in the subject by calculating a value of a formula using the amino acid concentration data of the subject obtained at the obtaining step and the formula previously established for evaluating the state of pancreatic cancer, including an explanatory variable to be substituted with the concentration value of the amino acid. The amino acid concentration data includes the concentration values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least two explanatory variables to be substituted with the concentration values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.

A problem to be solved by the present invention to perform an imaging mass spectrometry method capable of not only providing localization information of a biological substance in a single tissue section but also enabling quantitative comparison of an amount of a biological substance between multiple tissue sections.

By using a first derivatization reagent, a second derivatization reagent that is the isotopically-labeled first derivatization reagent, and a derivatized internal standard substance of a biological substance in the imaging mass spectrometry method, the amount of the biological substance can quantitatively be compared between multiple tissue sections.

Analogs and conjugates of β-Aminoisobutyric Acid (BAIB).

An evaluating method includes an evaluating step of evaluating a state of mild cognitive impairment for a subject to be evaluated, using (i) at least one value of concentration values of Put, α-ABA, Ala, Arg, Asn, Cit, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Taurine, 1-MeHis, 3-MeHis, aAAA, aAiBA, ADMA, Allyl Cys, bABA, bAiBA, Cystathionine, Cysteic acid, EtGly, GABA, hArg, Hypotaurine, Hypro, Kyn, Pyrazole-1-Ala, MCSO, MeCys, N6-AcLys, N8-AcSpd, Opthalmic acid, PEA, Pipecolic acid, Sar, SDMA, Spd, Spm, and Thioproline and test values of Alb, Folate, WBC, RBC, Hb, Ht, and PLT in blood of the subject, or (ii) a value of a formula including an explanatory variable to be substituted with the at least one value, calculated using the at least one value and the formula.

The present invention relates to a method for quantification of amino acids using a cell-free protein synthesis system. Specifically, the present invention relates to a method for quantification of amino acids, comprising: (a) preparing a reaction mixture for cell-free protein synthesis without target amino acids; (b) performing cell-free protein synthesis by mixing an assay sample containing target amino acids with the reaction mixture for cell-free protein synthesis; (c) measuring the signal intensity of the synthesized protein; and (d) calculating the concentration of the target amino acids by comparing the measured signal intensity with the standard concentration curve for each amino acid according to the protein signal produced using a standard sample, a method for providing information for diagnosing an amino acid metabolism-related disease using the same, a method for screening a material for prevention or treatment of an amino acid metabolism-related disease, and a method for screening a transaminase substrate. The method for quantification of amino acids according to the present invention can quantify amino acids in a short time at a low cost, and thus can be useful in various industries.

The present invention relates to a method for treating autism spectrum disorders (ASD) or ASD-like symptom, particularly by administering a zinc ion source and/or a serine component e.g. D-serine or its precursor/analogue, optionally in combination with a mixture of branched-chain amino acids (BCAAs). The present invention also relates to a combination, kit or composition for performing the method for treatment as described herein. Further described is use of a zinc ion source and/or a serine component and optional BCAAs for manufacturing a medicament for treating a symptom or disease characteristics associated with ASD or ASD-associated disorder or as a food supplement for ameliorating relevant symptoms in a subject in need thereof. The present invention further provides an animal model for autistic spectrum disorder (ASD) with deficient CTTNBP2 gene, and a method for identifying an ingredient effective in the treatment of ASD by using such animal model.

The invention relates to diagnostic methods for assessing the need of a subject for treatment with an anti-oxidant, or alternatively, for determining the utilization efficiency and ultimate effectiveness of anti-oxidant therapy in subjects having been treated with antioxidants. More specifically, the methods of the present invention are particularly useful in prophylactic assessment of individuals at risk for developing diseases or conditions in which oxidative stress plays a role, such that an appropriate therapeutic regimen can be prescribed for that individual, thus leading to alternative therapies and/or life style changes. The invention further relates to methods for assessing the need for, the utilization efficiency and the effectiveness of therapy in subjects having received therapy with specific antioxidant and immune enhancing formulations. Kits are also provided for measuring the levels of markers of oxidative stress and immune cell numbers.

Disclosed are processes for the production of composition comprising one or more fructose amino acids, said process comprising the steps of: (a) providing plant material derived from a botanical source selected from plants of the families Solanaceae, Compositae, (Asteraceae), Guttiferae, Umbelliferae, Papaveraceae, Vitidaceae or Acanthaceae; (b) extracting one or more fructose amino acid(s) from said plant material; and optionally (c) detecting the presence and/or measuring the amount of said fructose amino acid(s) in the extract of step (b).

The present disclosure features non-canonical or heavy isotope-containing amino acids, where the alpha-amino terminus and/or carboxylic acid terminus is modified with molecular cages. The molecular cage-modified amino acids are precluded from metabolic incorporation into proteins within living bacterial, plant, or mammalian cells, or from cell-free protein expression. Once uncaged, the amino acids are readily recognized by native and/or engineered tRNA synthetases, and can subsequently be incorporated into newly-synthesized proteins during protein translation.

The present invention provides a non-cryopreservation method that enables inexpensive and stable storage of feces. More specifically, the present invention provides: (A) a storage method of feces, the storage method including drying the feces in the presence of a solid desiccant; (B) a hermetic container including: (a) a solid desiccant; and (b) feces under the non-contact state with the solid desiccant; and (C) a feces fixing article including: (a) one or more members containing or fixing a solid desiccant; and (b) feces under the contact state with the solid desiccant. As the solid desiccant, a water absorbing solid desiccant such as silica Gel is preferred.